Bruce Hershatter is an Oncology physician affiliated with Emory Healthcare. OpenAlex indexes 66 publications with 528 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
40.9%alpha-Adrenergic Blocker40.9%Tamsulosin Hcl100%Part D≥42 patientsSensory organs
29.6%Fluoroquinolone Antibacterial29.6%Ciprofloxacin Hcl100%Part D≥44 patientsNervous system
20.9%Nonsteroidal Anti-inflammatory Drug20.9%Ibuprofen100%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial.
Journal of Clinical Oncology
2026 - Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States
Clinical Genitourinary Cancer
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Scott Fridkin, MD
Emory Healthcare
Ajay Premkumar, MD, MPH
Emory Healthcare
John Xerogeanes, MD
Emory Healthcare
Jay Varkey, MD
Emory Healthcare
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”